Similar articles

• Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

  Sorensen PS, Bertolotto A. Sorensen PS, et al. Neurology. 2007 Oct 9;69(15):1552; author reply 1553. doi: 10.1212/01.wnl.0000285763.31151.a6. Neurology. 2007. PMID: 17923618 No abstract available.
• Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

  Polman CH, Deisenhammer F, Giovannoni G, Killestein J, Schellekens H. Polman CH, et al. Neurology. 2007 Oct 9;69(15):1553-4; author reply 1555. doi: 10.1212/01.wnl.0000295671.79239.f1. Neurology. 2007. PMID: 17923619 No abstract available.
• Assessment and management of neutralizing antibodies in patients with multiple sclerosis.

  Hartung HP, Munschauer FE 3rd. Hartung HP, et al. J Neurol. 2004 Jun;251 Suppl 2:II40-2. doi: 10.1007/s00415-004-1207-4. J Neurol. 2004. PMID: 15264111
• Implications of neutralising antibodies on therapeutic efficacy.

  Bertolotto A. Bertolotto A. J Neurol Sci. 2009 Feb 1;277 Suppl 1:S29-32. doi: 10.1016/S0022-510X(09)70009-7. J Neurol Sci. 2009. PMID: 19200862 Review.
• Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

  Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Goodin DS, et al. Neurology. 2008 Sep 2;71(10):766-73. doi: 10.1212/01.wnl.0000320512.21919.d2. Neurology. 2008. PMID: 18765653 Review.